Skip to main content
OpenTrials
Completed

NCT Number: NCT01097525

Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery

To determine the effect of two types of wavefront modalities (WFG vs. WFO) and two types of refractive surgery (PRK vs. LASIK) on visual and military task performance after laser refractive surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Normal, healthy active adults with access to medical care at Walter Reed Health Care System.
  • Male or female at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  • Myopic spherical manifest refractive error from -1.00D up to -10.00D inclusive, with no more than 4.00D of manifest cylinder refractive error.
  • Inclusion based on pre-op Central Corneal Thickness (CCT) will be assessed according to Residual Stromal Bed Thickness
  • BSCVA of at least 20/20 in the study eye.
  • Soft contact lens users must have removed their lenses at least two weeks prior to baseline and follow-up measurements.
  • Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline and follow-up measurements.
  • Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50 diopters over the previous 12 months.
  • Exhibits strong motivation for keeping the follow-up visits.
  • Available for evaluation at Walter Reed during the 1 year follow-up period
  • If selected, willing and available to undergo testing at Ft. Belvoir during the study period.
  • All service members must have a signed command authorization to receive government sponsored refractive surgery. The signed command authorization will be included in the original application.
  • Access to transportation to meet follow-up requirements.

Exclusion criteria

  • Residual, recurrent or active ocular diseases or congenital corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, anterior basement membrane disease, recurrent erosions, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
  • History of any previous eye surgery or trauma, including previous refractive surgery.
  • Dry eye as reflected by Schirmer's test, subjective complaints or symptoms of dry eye, findings during slit lamp exam that would be consistent with dry eye (e.g. superficial punctuate keratitis).
  • Corneal thickness insufficient to allow the residual remaining stromal bed to be no less than 300 microns in each eye. The residual stromal bed thickness will be determined by subtracting both the LASIK flap thickness and depth of the ablation from the total central corneal thickness measured by pachymetry.
  • Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. This is standard of care exclusion for refractive surgery at the Walter Reed Refractive Surgery Center because of the medications that are routinely given as part of the procedures. Standard of care analgesia consists of medications (e.g. narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not known, however, physical dependence in the neonate may occur if the mother is given narcotics. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy.
  • Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
  • Significant corneal neovascularization.
  • Progressive myopia or keratoconus.
  • Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  • Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
  • Any physical or mental impairment which would preclude participation in any of the examinations.
  • Inability to meet the mandated follow-up visit schedule for any reason such as duty hours, impending deployments, or PCS.

Treatment and study plan

WFG PRK

Procedure

WFG LASIK

Procedure

WFO PRK

Procedure

WFO LASIK

Procedure

Primary outcomes

  1. visual outcomes

    Time frame: 12 months postoperatively

    Visual outcomes will be measured in terms of:

    • number of eyes achieving uncorrected visual acuity (UDVA) 20/20 or better.
    • number of eyes maintaining one Snellen line of corrected distance visual acuity (CDVA).
    • number of eyes within 0.50 diopter of manifest spherical equivalent.
  2. objective image quality

    Time frame: 12 months postoperatively

    as measured by wavefront aberrometry

  3. military task performance

    Time frame: 6 months postoperatively

    as measured by threshold target identification and night firing range

  4. visual performance

    Time frame: 12 months postoperatively

    as measured by contrast sensitivity

Sponsors and collaborators

Lead sponsor

Fort Belvoir Community Hospital

Fed

Collaborators

  • US Army Night Vision and Electronic Sensors Directorate
  • Walter Reed National Military Medical Center

Registry information

Important dates

Study start
2010
Primary completion
2014
Study completion
2014
First posted
Apr 1, 2010
Registry last updated
Mar 13, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.